Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation in new indications
Collaboration will leverage ENLIGHT, a pan-cancer response predictor scalable to all cancer types and all targeted and immune checkpoint blockade (ICB) oncology drugs
https://finance.yahoo.com/news/onconova-therapeutics-pangea-biomed-enter-120000239.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.